Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 31,421 shares, a drop of 38.5% from the April 15th total of 51,122 shares. Based on an average daily trading volume, of 23,330 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.1% of the shares of the company are short sold.
Zhengye Biotechnology Trading Up 0.3%
Shares of ZYBT stock traded up $0.00 on Friday, hitting $0.95. 4,401 shares of the stock traded hands, compared to its average volume of 70,488. The firm’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.31. The company has a current ratio of 1.14, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03. Zhengye Biotechnology has a twelve month low of $0.68 and a twelve month high of $13.08.
Zhengye Biotechnology (NASDAQ:ZYBT – Get Free Report) last posted its earnings results on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The business had revenue of $3.97 million for the quarter.
Wall Street Analyst Weigh In
View Our Latest Analysis on ZYBT
Institutional Trading of Zhengye Biotechnology
Several hedge funds have recently made changes to their positions in ZYBT. Jane Street Group LLC purchased a new stake in shares of Zhengye Biotechnology during the second quarter worth approximately $1,158,000. WINTON GROUP Ltd increased its stake in shares of Zhengye Biotechnology by 193.8% during the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock worth $73,000 after buying an additional 41,750 shares during the period. Invesco Ltd. purchased a new stake in shares of Zhengye Biotechnology during the second quarter worth approximately $220,000. Geode Capital Management LLC purchased a new stake in shares of Zhengye Biotechnology during the second quarter worth approximately $174,000. Finally, XTX Topco Ltd increased its stake in shares of Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after buying an additional 24,697 shares during the period.
Zhengye Biotechnology Company Profile
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
